CL2016000597A1 - Derivados de desoxino jirimicina y sus métodos de uso. - Google Patents

Derivados de desoxino jirimicina y sus métodos de uso.

Info

Publication number
CL2016000597A1
CL2016000597A1 CL2016000597A CL2016000597A CL2016000597A1 CL 2016000597 A1 CL2016000597 A1 CL 2016000597A1 CL 2016000597 A CL2016000597 A CL 2016000597A CL 2016000597 A CL2016000597 A CL 2016000597A CL 2016000597 A1 CL2016000597 A1 CL 2016000597A1
Authority
CL
Chile
Prior art keywords
jirimicina
deoxino
derivatives
methods
deoxinojirimicine
Prior art date
Application number
CL2016000597A
Other languages
English (en)
Inventor
Urban Ramstedt
Raju Penmasta
Hitesh Batra
Tam Nguyen
Original Assignee
Emergent Virology Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emergent Virology Llc filed Critical Emergent Virology Llc
Publication of CL2016000597A1 publication Critical patent/CL2016000597A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

<p>COMPUESTOS DERIVADOS DE DESOXINOJIRIMICINA N-SUSTITUIDA; COMPOSIICION FARMACEUTICA; Y SU USO PARA EL TRATAMIENTO DEL DENGUE Y LA INFLUENZA TIPO A</p>
CL2016000597A 2013-09-16 2016-03-14 Derivados de desoxino jirimicina y sus métodos de uso. CL2016000597A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361878286P 2013-09-16 2013-09-16

Publications (1)

Publication Number Publication Date
CL2016000597A1 true CL2016000597A1 (es) 2017-02-24

Family

ID=52666528

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016000597A CL2016000597A1 (es) 2013-09-16 2016-03-14 Derivados de desoxino jirimicina y sus métodos de uso.

Country Status (18)

Country Link
US (1) US10144727B2 (es)
EP (1) EP3046558B1 (es)
JP (1) JP6456393B2 (es)
KR (1) KR20160055916A (es)
CN (1) CN105636589B (es)
AP (1) AP2016009125A0 (es)
AU (1) AU2014318488B2 (es)
BR (1) BR112016005417A8 (es)
CA (1) CA2924026C (es)
CL (1) CL2016000597A1 (es)
CR (1) CR20160178A (es)
HK (1) HK1222129A1 (es)
IL (1) IL244446A0 (es)
MX (1) MX2016003323A (es)
PH (1) PH12016500465A1 (es)
RU (1) RU2702133C2 (es)
SG (1) SG11201601646YA (es)
WO (1) WO2015039010A2 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3094615A4 (en) 2014-01-13 2017-11-08 P2 Science, Inc. Terpene-derived acids and esters and methods for preparing and using same
JP6687547B2 (ja) 2014-06-20 2020-04-22 ピー２ サイエンス，インコーポレイティド 管式又は多管式反応器における膜オゾン分解
WO2016022803A2 (en) * 2014-08-06 2016-02-11 P2 Science, Inc. Fragrances from the esters of fatty acids
US10428022B2 (en) 2014-11-05 2019-10-01 Emergent Virology Llc Iminosugars useful for the treatment of viral diseases
WO2017201030A1 (en) * 2016-05-16 2017-11-23 Emergent Virology Llc Methods of treating viral infection
US20190282558A1 (en) * 2016-05-16 2019-09-19 Emergent Virology Llc Methods of Treating Zika Virus Infection
EP3472124A4 (en) 2016-06-21 2020-03-04 P2 Science, Inc. CONTINUOUS FLOW REACTORS FOR THE CONTINUOUS EXTINCTION OF PEROXIDE MIXTURES AND METHODS COMPRISING SAME
US10696605B2 (en) 2016-09-16 2020-06-30 P2 Science, Inc. Uses of vanadium to oxidize aldehydes and ozonides
CN111904959A (zh) * 2020-08-21 2020-11-10 牡丹江医学院 α-L-岩藻糖苷酶抑制剂在制备治疗小儿肺炎的药物中的用途

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2758025A1 (de) * 1977-12-24 1979-07-12 Bayer Ag Neue derivate von 3,4,5-trihydroxypiperidin, verfahren zu ihrer herstellung und ihre verwendung
DE2834122A1 (de) 1978-08-03 1980-02-14 Bayer Ag Verfahren zur herstellung von 6-amino-6-desoxy-l-sorbose
DE2853573A1 (de) 1978-12-12 1980-07-03 Bayer Ag Herstellung von n-substituierten derivaten des l-desoxynojirimycins
DE3007078A1 (de) * 1980-02-26 1981-09-10 Bayer Ag, 5090 Leverkusen Neue derivate von 3,4,5-trihydroxypiperidin, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel sowie in der tierernaehrung
DE3038901A1 (de) 1980-10-15 1982-05-06 Bayer Ag, 5090 Leverkusen Verfahren zur herstellung von n-substituierten derivaten des 1-desoxynojirimycins
DE3611841A1 (de) 1986-04-09 1987-10-15 Bayer Ag Verfahren zur herstellung von 1-desoxynojirimycin und dessen n-derivaten
US5103008A (en) 1989-08-17 1992-04-07 Monsanto Company Compound, N-butyl-deoxynojirimycin-6-phosphate
US5043273A (en) 1989-08-17 1991-08-27 Monsanto Company Phosphorylated glycosidase inhibitor prodrugs
US4994572A (en) 1989-10-12 1991-02-19 Monsanto Company Synthesis of nojirimycin derivatives
US5200523A (en) 1990-10-10 1993-04-06 Monsanto Company Synthesis of nojirimycin derivatives
AU1876095A (en) 1994-02-25 1995-09-11 G.D. Searle & Co. Use of 1-deoxynojirimycin and its derivatives for treating mammals infected with respiratory syncytial virus
US20030100532A1 (en) 1997-02-14 2003-05-29 Gary S. Jacob Use of n-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds in combination therapy for treating hepatitis virus infections
EP1037636A4 (en) 1997-12-11 2004-08-18 Univ Oxford INHIBITATION OF MEMBRANE-TIED VIRAL REPLICATION
US6689759B1 (en) 1998-02-12 2004-02-10 G. D. Searle & Co. Methods of Treating hepatitis virus infections with N-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds in combination therapy
GB9828474D0 (en) 1998-12-24 1999-02-17 British Aerospace Surface topology inspection
CA2362914C (en) 1999-02-12 2009-04-14 G.D. Searle & Co. Use of substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds for treating hepatitis virus infections
ES2302697T3 (es) 1999-08-10 2008-08-01 The Chancellor, Masters And Scholars Of The University Of Oxford Compuestos n-alquilicos de cadena larga y derivados oxa de los mismos y uso como composiciones antivirales.
US7256005B2 (en) 1999-08-10 2007-08-14 The Chancellor, Masters And Scholars Of The University Of Oxford Methods for identifying iminosugar derivatives that inhibit HCV p7 ion channel activity
US7427758B2 (en) 2003-05-28 2008-09-23 Opto-Knowledge Systems, Inc. Cryogenically cooled adjustable apertures for infra-red cameras
FR2861991B1 (fr) * 2003-11-07 2008-01-18 Centre Nat Rech Scient Utilisation d'inhibiteurs de glucosidase pour une therapie de la mucoviscidose
WO2007140184A2 (en) 2006-05-24 2007-12-06 United Therapeutics Corporation Deoxynojirimycin and d-arabinitol analogs and methods of using
WO2008088581A2 (en) 2006-08-02 2008-07-24 United Therapeutics Corporation Liposome treatment of viral infections
US8097728B2 (en) * 2007-04-30 2012-01-17 Philadelphia Health & Education Corporation Iminosugar compounds with antiflavirus activity
WO2009118658A2 (en) 2008-03-26 2009-10-01 University Of Oxford Endoplasmic reticulum targeting liposomes
US9040488B2 (en) * 2008-09-02 2015-05-26 Baruch S. Blumberg Institute Imino sugar derivatives demonstrate potent antiviral activity and reduced toxicity
KR20120042716A (ko) * 2009-02-23 2012-05-03 유나이티드 세러퓨틱스 코오포레이션 이미노슈가 및 바이러스성 질환을 치료하는 방법
ES2562635T3 (es) 2009-02-24 2016-03-07 United Therapeutics Corporation Iminoazúcares y métodos de tratamiento de infecciones producidas por arenavirus
CA2757026A1 (en) 2009-03-27 2010-09-30 The Chancellor, Masters And Scholars Of The University Of Oxford Cholesterol level lowering liposomes
US8426445B2 (en) 2009-06-12 2013-04-23 United Therapeutics Corporation Iminosugars and methods of treating bunyaviral and togaviral diseases
ES2527623T3 (es) 2009-09-04 2015-01-27 United Therapeutics Corporation Iminoazúcares para su uso en el tratamiento de enfermedades por filovirus
WO2011028775A1 (en) * 2009-09-04 2011-03-10 United Therapeutics Corporation Methods of treating orthomyxoviral infections
CN102625801B (zh) 2009-09-04 2015-09-09 联合治疗公司 治疗痘病毒感染的方法
WO2014017915A2 (en) 2012-07-27 2014-01-30 Universiteit Utrecht Holding B.V. Urea and guanidinium derivatives of iminosugars

Also Published As

Publication number Publication date
US20160221993A1 (en) 2016-08-04
HK1222129A1 (zh) 2017-06-23
WO2015039010A3 (en) 2015-05-07
KR20160055916A (ko) 2016-05-18
JP6456393B2 (ja) 2019-01-23
PH12016500465B1 (en) 2016-05-16
RU2702133C2 (ru) 2019-10-04
BR112016005417A8 (pt) 2020-02-18
IL244446A0 (en) 2016-04-21
CA2924026A1 (en) 2015-03-19
CN105636589B (zh) 2019-07-23
RU2016111704A3 (es) 2018-06-09
CA2924026C (en) 2021-12-28
PH12016500465A1 (en) 2016-05-16
AP2016009125A0 (en) 2016-04-30
AU2014318488A1 (en) 2016-04-21
EP3046558A4 (en) 2017-06-07
AU2014318488A2 (en) 2016-04-28
US10144727B2 (en) 2018-12-04
SG11201601646YA (en) 2016-04-28
MX2016003323A (es) 2016-08-12
CN105636589A (zh) 2016-06-01
AU2014318488B2 (en) 2019-03-07
EP3046558A2 (en) 2016-07-27
CR20160178A (es) 2016-08-08
RU2016111704A (ru) 2017-10-23
WO2015039010A2 (en) 2015-03-19
JP2016530332A (ja) 2016-09-29
EP3046558B1 (en) 2019-08-14

Similar Documents

Publication Publication Date Title
DOP2017000078A (es) Indazoles sustituidos con bencilo como inhibidores de bub1.
CL2016000597A1 (es) Derivados de desoxino jirimicina y sus métodos de uso.
CY1123633T1 (el) Ετεροκυκλικες ενωσεις και οι χρησεις αυτων
CL2016003398A1 (es) Compuestos de heteroarilo útiles como inhibidores de enzima activadora de sumo.
CL2016002027A1 (es) Ciclopropilamina como inhibidor de la lsd1
CL2016000153A1 (es) Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b
DOP2017000176A (es) Derivados de 4h-pirrol[3,2-c]piridin-4-ona
CL2016000807A1 (es) Amino heteroarilo benzamidas como inhibidores de quinasa.
UY35485A (es) Compuestos heterocíclicos y usos de los mismos
BR112016015706A2 (pt) composto, uso do mesmo e composição farmacêutica
CL2015003395A1 (es) Derivados pirazolopirrolidina y su uso en el tratamiento de la enfermedad
DOP2015000219A (es) Compuestos de heteroarilo y sus usos
CL2015002932A1 (es) Inhibidores de proteína quinasa
EA201790785A1 (ru) Производные тетрагидроизохинолина
CL2015002767A1 (es) Compuestos terapéuticos y composiciones
CL2015003735A1 (es) Compuestos heteroaromáticos y su uso como ligandos d1 de dopamina
GT201700023A (es) Derivados de heterociclico opcionalmente condensados de piridimina útiles para el tratamiento de enfermedades inflamatorias, metabolicas, oncológicas y autoinmunitarias
CL2016001973A1 (es) Derivados de nucleosido sustituidos con 4&#39; -difluorometilo como inhibidores de la replicación de arn de la influenza.
DK3539961T3 (da) Polycykliske amidderivativer som cdk9-inhibitorer
CL2015003357A1 (es) Derivados de nucleósidos 4&#39;-fluoro-2&#39;-metil sustituidos
SV2018005760A (es) Derivados de aminotiazol utiles como agentes antiviricos
CL2015000976A1 (es) Compuestos de 2-fenil-5-heterociclil-tetrahidro-2h-piran-3-amina para uso en el tratamiento de diabetes y sus trastornos asociados.
DOP2016000170A (es) Compuestos derivados de hidroxiformamida y usos del mismo
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
CL2015002180A1 (es) Terapia de combinación para el tratamiento de neumonía nosocomial